Abemaciclib is a medication used in this trial to help treat certain types of cancer. It works by blocking proteins that promote the growth of cancer cells, potentially slowing down or stopping the progression of the disease.

Letrozole is another medication involved in the trial. It is used to treat hormone receptor-positive cancers by lowering estrogen levels in the body, which can help slow or stop the growth of cancer cells that need estrogen to grow.

Low-grade serous ovarian cancer – This is a type of ovarian cancer characterized by slow-growing tumors that originate from the surface of the ovary. It is less aggressive compared to other forms of ovarian cancer and often affects younger women. The disease typically presents with symptoms such as abdominal bloating, pelvic pain, and changes in bowel habits. Over time, the cancer may spread to nearby tissues and organs within the pelvis and abdomen. It is known for its resistance to conventional chemotherapy, making management challenging. The progression is generally slower, but it requires careful monitoring and management.

Adult-type granulosa cell tumor – This is a rare form of ovarian tumor that arises from the sex-cord stromal cells of the ovary. It is known for its potential to produce hormones, particularly estrogen, which can lead to symptoms like abnormal uterine bleeding or menstrual irregularities. The tumor is typically slow-growing and may not cause symptoms until it reaches a significant size. It can sometimes be detected during routine pelvic examinations or imaging studies. Although it is generally considered less aggressive, it can recur many years after initial treatment. The disease requires long-term follow-up due to its potential for late recurrence.